Dr Brian Tse
BMedSc(Hon), DipInnovMan, PhD (all UNSW)
Senior Preclinical Imaging Scientist
Projects
About me
Dr Tse has been the Senior Preclinical Imaging Scientist at TRI since 2015. He provides expertise to researchers on in vivo imaging in a collaborative manner, including image acquisition, data analysis, experimental design, project development, grant submissions, ethics applications, and publications.
He is highly experienced in preclinical imaging technologies: 1) microCT, 2) microPET-CT, 3) image-guided radiation therapy, 4) optical (bioluminescence, fluorescence), 5) high-frequency ultrasound, 6) photoacoustics, 7) nuclear magnetic resonance, 8) planar X-ray, 9) gamma counting, and 10) radionuclide therapy (alpha and beta).
Dr Tse completed his PhD from UNSW in 2010 in the field of cancer immunotherapy, where he gained expertise in cutting-edge imaging modalities (optical imaging, ultrasound and microCT). He then undertook a two-year post-doctoral position at the Lowy Cancer Research Centre in Sydney researching on ovarian cancer. In 2012, he moved to Brisbane to join QUT to work on several projects including prostate cancer imaging and elucidating the molecular drivers of disease progression.
Dr Tse has received funding from the USA Department of Defence (Post-doc Fellowship), NHMRC (Project grant), QUT (ECR grant) and TRI (infrastructure grants). In total, he has attracted >$2m in research funding towards research projects and research infrastructure. He has 30 publications, in journals that include Oncogene, Cell, Theranostics, Small, European Journal of Nuclear Medicine and Molecular Imaging Research, and Annals of Oncology.
Dr Tse also holds visiting scientist appointments with QUT and UQ.
He has a Diploma In Innovation Management degree (UNSW) and completed several management and leadership courses through the Australian Institute of Management (AIM).
Publications
30. Keshvari S, Masson JJR, Ferrari-Cestari M, Bodea LG, Nooru-Mohamed F, Tse BWC, Sokolowski KA, Batoon L, Patkar OL, Sullivan MA, Ebersbach H, Stutz C, Parton RG, Summers KM, Pettit AR, Hume DA, Irvine KM. Reversible expansion of tissue macrophages in response to macrophage colony-stimulating factor (CSF1) transforms systemic lipid and carbohydrate metabolism. Am J Physiol Endocrinol Metab. 2023 Dec 20. doi: 10.1152/ajpendo.00347.2023.. PMID: 38117267.
29. Thomas PB, Alinezhad S, Joshi A, Sweeney K, Tse BWC, Tevz G, McPherson S, Nelson CC, Williams ED, Vela I. Introduction of Androgen Receptor Targeting shRNA Inhibits Tumor Growth in Patient-Derived Prostate Cancer Xenografts. Current Oncology. 2023; 30(11):9437-9447. doi:10.3390/curroncol30110683
28. Fithri NA, Wu Y, Cowin G, Akhtar F, Tran HDN, Tse B, Westra van Holthe N, Moonshi SS, Peter K, Wang X, Truong NP, Ta HT. Gold-Iron nanoparticle: A unique multimodal theranostic approach for thrombosis. Applied Materials Today. 2023 Vol 31, Apr 101750. doi: 10.1016/j.apmt.2023.101750
27. Vazquez-Prada KX, Moonshi SS, Wu Y, Akther F, Tse BWC, Sokolowski KA, Peter K, Wang X, Xu G, Ta HT. A Spiky Silver-Iron Oxide Nanoparticle for Highly Efficient Targeted Photothermal Therapy and Multimodal Imaging of Thrombosis. Small. 2023 Jan 12:e2205744. doi: 10.1002/smll.202205744.
26. Khan T, Lyons NJ, Gough M, Kwah KKX, Cuda TJ, Snell CE, Tse BW, Sokolowski KA, Pearce LA, Adams TE, Rose SE, Puttick S, Pajic M, Adams MN, He Y, Hooper JD, Kryza T. CUB Domain-Containing Protein 1 (CDCP1) is a rational target for the development of imaging tracers and antibody-drug conjugates for cancer detection and therapy. Theranostics 2022; 12(16):6915-6930. doi:10.7150/thno.78171.
25. Singh A, Qu Z, Sharma A, Singh M, Tse B, Ostrikov K, Popat A, Sonar P, Kumeria T. Ultra-bright green carbon dots with excitation-independent fluorescence for bioimaging. J Nanostruct Chem (2022). Doi: 10.1007/s40097-022-00501-5
24. Keshvari S, Genz B, Teakle N, Caruso M, Cestari MF, Patkar OL, Tse BWC, Sokolowski KA, Ebersbach H, Jascur J, MacDonald KPA, Miller G, Ramm GA, Pettit AR, Clouston AD, Powell EE, Hume DA, Irvine KM. Therapeutic potential of macrophage colony-stimulating factor (CSF1) in chronic liver disease. Dis Model Mech. 2022 Feb 16:dmm.049387. doi: 10.1242/dmm.04938
23. Cuda TJ, He Y, Kryza T, Khan T, Tse BW, Sokolowski KA, Liu C, Lyons N, Gough M, Snell CE, Wyld DK, Rose S, Riddell AD, Stevenson ARL, Thomas PA, Clark DA, Puttick S, Hooper JD. Preclinical molecular PET-CT imaging targeting CDCP1 in colorectal cancer. Contrast Media Mol Imaging 2021; doi 10.1155/2021/3153278
22. Mills RJ, Humphrey SJ, Fortuna PRJ, Lor M, Foster SR, Quaife-Ryan GA, Johnston RL, Dumenil T, Bishop C, Rudraraju R, Rawle DJ, Le T, Zhao W, Lee L, Mackenzie-Kludas C, Mehdiabadi NR, Halliday C, Gilham D, Fu L, Nicholls SJ, Johansson J, Sweeney M, Wong NCW, Kulikowski E, Sokolowski KA, Tse BWC, Devilée L, Voges HK, Reynolds LT, Krumeich S, Mathieson E, Abu-Bonsrah D, Karavendzas K, Griffen B, Titmarsh D, Elliott DA, McMahon J, Suhrbier A, Subbarao K, Porrello ER, Smyth MJ, Engwerda CR, MacDonald KPA, Bald T, James DE, Hudson JE. BET inhibition blocks inflammation-induced cardiac dysfunction and SARS-CoV-2 infection. Cell. 2021 Mar 16:S0092-8674(21)00354-8. doi: 10.1016/j.cell.2021.03.026.
21.Tse BW-C, Kryza T, Yeh MC, Dong Y, Sokolowski KA, Walpole C, Dreyer T, Felber J, Harris J, Magdolen V, Russell PJ, Clements JA. KLK4 induces anti-tumor effects in human xenograft mouse models of orthotopic and metastatic prostate cancer. Cancers. 2020.12(12):3501. doi: 10.3390/cancers12123501.
20. Wang H, Burke LJ, Patel J, Tse BW-C, Bridle KR, Cogger VC, Li X, Liu X, Yang H, Crawford DHG, Roberts MS, Gao W, Liang X. Imaging-based vascular-related biomarkers for early detection of acetaminophen-induced liver injury. Theranostics. 2020. doi:10.7150/thno.44900
19. Yeh MC, Tse BWC, Fletcher NL, Houston ZH, Lund M, Volpert M, Stewart C, Sokolowski KA, Jeet V, Thurecht KJ, Campbell DH, Walsh BJ, Nelson CC, Russell PJ. Targeted beta therapy of human prostate cancer in vivo with Lu-177 labelled Miltuximab® antibody against glypican-1 (GPC-1). European Journal of Nuclear Medicine and Molecular Imaging Research 2020. 10, 46 doi: 10.1186/s13550-020-00637-x .
18. Siegers JY, Novakovic B, Hulme KD, Marshall R, Bloxham CJ, Thomas WG, Reichelt ME, Leijten L, van Run P, Knox K, Sokolowski KA, Tse BW-C, Chew KY, Christ AN, Howe G, Bruxner TJC, Karolyi M, Pawelka E, Koch RM, Bellman-Weiler RM, Burkert F, Weiss G, Samanta RJ, Openshaw PJM, Bielefeldt-Ohmann H, van Riel D, and Short KR. A high fat diet increases influenza-A virus-associated cardiovascular damage. The Journal of Infectious Diseases. 2020. doi:10.1093/infdis/jiaa159
17. Kryza T, Khan T, Puttick S , Li C , Sokolowski KA, Tse BW-C, Cuda T, Lyons N, Gough M, Yin J, Parkin A, Deryugina EI, Quigley JP, Law RHP, Whisstock JC, Riddell AD, Barbour AP, Wyld DK, Thomas PA, Rose S, Snell CE, Pajic M, He Y, Hooper JD. Effective targeting of intact and proteolysed CDCP1 for imaging and treatment of 1 pancreatic ductal adenocarcinoma. Theranostics. 2020; 10(9):4116-4133; doi:10.7150/thno.43589.
16. Harrington BS, He Y, Khan T, Puttick S, Conroy PJ, Kryza T, Cuda T, Sokolowski KA, Tse BW-C, Robbins KK, Arachchige BJ, Stehbens SJ, Pollock PM, Reed S, Weroha SJ, Haluska P, Salomon C, Lourie R, Perrin LC, Law RH, Whistock JC, Hooper JD. Anti-CDCP1 immuno-conjugates for detection and inhibition of ovarian cancer. Theranostics. 2020 10(5):2095-2114 doi:10.7150/thno.30736
15. Chaudhary Z, Khan GM, Abeer MM, Pujara N, Tse BW-C, McGuckin MA, Popat M, Kumeria T. Efficient photoacoustic imaging using ICG loaded functionalized mesoporous silica nanoparticles. Biomaterials Science, 2019.7, 5002-5015
14. Huang X, Ali T, Nano T, Blick T, Tse BW-C, Sokolowski K, Tourell MC, Lloyd T, Thompson EW, Momot KI, Hugo HJ. Quantification of breast tissue density: Correlation between single-sided portable NMR and micro-CT measurements. Magnetic Resonance Imaging. 2019: 62:110-120
13. Wang H, Li X, Tse BW-C, Yang H, Thorling CA, Liu Y, Touraud M, Chouane JB, Liu X, Roberts MS, Liang X. Indocyanine green-incorporating nanoparticles for cancer theranostics. Theranostics 2018; 8(5):1227-1242.
12. Tse BW-C*, Volpert M*, Ratther E*, Stylianou N, Nouri M, McGowan K, Lehman ML, McPherson SJ, Roshan-Moniri M, Butler M, Caradec J, Gregory-Evans CY, McGovern J, Das R, Takhar M, Erho N, Alshalafa M, Davicioni E, Schaeffer EM, Jenkins RB, Ross AE, Karnes RJ, Den RB, Fazli L, Gregory PA, Gleave ME, Williams ED, Rennie PS, Buttyan R, Gunter JH, Selth LA, Russell PJ, Nelson CC & Hollier BG. Neuropilin-1 is up-regulated in the adaptive response of prostate tumors to androgen targeted therapies and is prognostic of metastastic progression and patient mortality. Oncogene. 2017. doi: 10.1038/onc.2016.482. * Equal first.
11. Rhee H, Ng KL, Tse BW-C, Yeh MC, Russell PJ, Nelson CC, Samaratunga H, Thomas, T, Vela I, Gobe G, Wood S. Using Prostate Specific Membrane Antigen (PSMA) Expression In Clear Cell Renal Cell Carcinoma For Imaging Advanced Disease. Pathology. 2016. doi: 10.1016/j.pathol.2016.05.011
10. Fuchs AV*, Tse BW-C*, Pearce AK, Yeh MC, Fletcher N, Huang SS, Heston WD, Whittaker AK, Russell PJ, Thurecht K. Evaluation of polymeric nanomedicines targeted to PSMA: Effect of ligand on targeting efficiency.Biomacromolecules. 2015: 16 (10), pp 3235–3247 doi: 10.1021/acs.biomac.5b00913. *Equal first.
9. Russell PJ, Russell P, Rudduck C, Tse BW-C, Williams ED. Raghavan D. Establishing prostate cancer patient derived xenografts: lessons learned from older studies. The Prostate. 2015. doi: 10.1002/pros.22946
8. Tse BW-C, Cowin G, Soekmadji C, Jovanovic L, Vasireddy RS, Ling M-T, Khatri A, Liu TQ, Thierry B, Russell PJ. PSMA-targeting iron oxide magnetic nanoparticles enhance MRI of preclinical prostate cancer. Nanomedicine. 2014. doi: 10.2217/NNM.14.122.
7. Pearce AK, Rolfe B, Russell PJ, Tse BW-C, Whittaker AK, Fuchs AV, Thurecht KJ. Development of a polymer theranostic for prostate cancer. Polymer Chemistry. 2014. doi:10.1039/C4PY00999A.
6. Tse BW-C, Jovanovic L, Nelson CC, de Souza P, Power CA, Russell PJ. From bench to bedside: immunotherapy for prostate cancer. Biomed Research International 2014. Article ID 981434, 11 pages. doi:10.1155/2014/981434.
5. Jacob F, Anugraham M, Alam S, Tse BW-C, Pochechueva T, Guertler R, Bovin NV, Fedier A, Hacker NF, Huflejt MF, Packer N, Heinzelmann-Schwarz V. The Glycosphingolipid P1 Is an Ovarian Cancer-Associated Carbohydrate Antigen Involved in Migration. British Journal of Cancer. 2014. doi: 10.1038/bjc.2014.455
4. Tse BW-C, Collins A, Oehler MK, Collins A, Zipplelius A, Heinzelmann-Schwarz V. Antibody-based immunotherapy for ovarian cancer – where are we at? Annals of Oncology. 2013. doi:10.1093/annonc/mdt405
3. Buehler M, Tse BW-C, Leboucq A, Jacob F, Caduff R, Fink D, Goldstein D, Heinzelmann-Schwarz V. Meta-analysis of microarray data identifies GAS6 as an independent predictor of poor survival in ovarian cancer, BioMed Research International, 2013, Article ID 238284, 9 pages, 2013. doi:10.1155/2013/238284
2. Tse BW-C, Scott KF, Russell PJ. Paradoxical Roles of Tumour Necrosis Factor-Alpha in Prostate Cancer Biology.Prostate Cancer. 2012; Article ID 128965, 8 pages. doi:10.1155/2012/128965
1. Tse BW-C, Russell PJ, Lochner M, Forster I, Power CA. IL-18 Inhibits Growth of Murine Orthotopic Prostate Carcinomas via Both Adaptive and Innate Immune Mechanisms. PLoS ONE 2011; 6(9):e24241. doi:10.1371/journal.pone.0024241
Grants and Funding
Events / Articles
Research fields
Connect
